Qinecsa Solutions acquires Insife to strengthen pharmacovigilance technology

By Liza Laws

- Last updated on GMT

© Getty Images
© Getty Images

Related tags Pharmacovigilance Drug safety Fda Clinical trial Pharmaceutical industry

Qinecsa Solutions (Qinecsa), a lead company in technology-driven end-to-end pharmacovigilance solutions has announced its acquisition of Insife ApS (Insife), a Danish-based firm specializing in innovative pharmacovigilance platforms.

This strategic move, the company says, aligns with Qinecsa's vision to emerge as the premier provider of digital pharmacovigilance solutions.

With a strong focus on innovation and excellence, Qinecsa says it has earned a reputation as a trusted global partner in pharmacovigilance. With platforms like Reportum and CVW, Qinecsa believes it empowers life science companies to efficiently capture, manage, and assess drug safety data across the entire drug life cycle.

Insife is known for its HALOPV platform, and tells OSP it is a global player in pharmacovigilance software, technology, and consultancy. HALOPV, it says, is recognized for its multivigilance capabilities, offers end-to-end management of PV processes and is available as an enterprise-grade technology or in a cost-effective SaaS model. Additionally, Insife's Global Regulatory Intelligence for Pharmacovigilance (GRIP) club provides valuable insights and networking opportunities for PV professionals.

The acquisition of Insife aims to bolster Qinecsa's position as a leader in pharmacovigilance solutions and technologies. By combining their industry expertise, Qinecsa and Insife say they aim to offer an enhanced suite of services to pharmaceutical companies and regulatory agencies worldwide.

John Gillie, CEO of Qinecsa Solutions, said: "Welcoming Insife to the Qinecsa family marks a significant milestone in our journey. By integrating Insife's cutting-edge technology and consultancy services, we are poised to deliver greater value to our customers globally."

The acquisition enables Qinecsa to leverage Insife's software development expertise to enhance its pharmacovigilance services and drive innovation in the field. Together, Qinecsa and Insife say they are fully committed to advancing patient safety, drug development, and regulatory compliance through AI-driven technologies.

Martin Holm-Petersen, CEO of Insife, echoed his enthusiasm about the merger, emphasizing the opportunities it presents for both companies and their clients. "Joining Qinecsa is a strategic move that will expand our global reach and capabilities," he said. "Together, we will drive positive outcomes for the pharmaceutical industry."

Qinecsa Solutions operates under the umbrella of Stanley Capital Partners, further solidifying its position as a key player in the pharmacovigilance landscape.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Related suppliers

Follow us


View more